Lamotrigine (All indications) updated on 04-22-2025

Urinary malformations

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17498
R73513		 Wiggs (Epilepsy) (Lamotrigine), 2024 Urinary system malformations early pregnancy population based cohort retrospective unexposed, sick Adjustment: Yes 1.17 [0.48;2.86] -/1,412   -/9,364 - 1,412
ref
S8924
R48251		 Thomas (Lamotrigine) (Controls unexposed, sick), 2021 Urinary malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 1.14 [0.13;9.64] C 1/50   6/340 7 50
ref
Total 2 studies 1.16 [0.51;2.65] 7 1,462
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Wiggs (Epilepsy) (Lamotrigine), 2024Wiggs, 2024 1 1.17[0.48; 2.86]-1,41285%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Thomas (Lamotrigine) (Controls unexposed, sick), 2021Thomas, 2021 2 1.14[0.13; 9.64]75015%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.16[0.51; 2.65]71,4620.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Epilepsy) (Lamotrigine; 2: Lamotrigine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.16[0.51; 2.65]71,4620%NAWiggs (Epilepsy) (Lamotrigine), 2024 Thomas (Lamotrigine) (Controls unexposed, sick), 2021 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.16[0.51; 2.65]71,4620%NAWiggs (Epilepsy) (Lamotrigine), 2024 Thomas (Lamotrigine) (Controls unexposed, sick), 2021 2 Tags Adjustment   - No  - No 1.14[0.13; 9.64]750 -NAThomas (Lamotrigine) (Controls unexposed, sick), 2021 1   - Yes  - Yes 1.17[0.48; 2.86]-1,412 -NAWiggs (Epilepsy) (Lamotrigine), 2024 1 All studiesAll studies 1.16[0.51; 2.65]71,4620%NAWiggs (Epilepsy) (Lamotrigine), 2024 Thomas (Lamotrigine) (Controls unexposed, sick), 2021 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.16[0.51; 2.65]71,4620%NAWiggs (Epilepsy) (Lamotrigine), 2024 Thomas (Lamotrigine) (Controls unexposed, sick), 2021 20.510.01.0